A Biotech Entrepreneur Aims to Help Us Stay Young While Growing Old

Small molecule development, in the sense of changing the parameters of your candidate in a desired direction in a class of molecules, is slow and expensive and to a certain extent reliant on good fortune. You can't just reliably and cheaply dial up the effectiveness or adjust with tissue specificity.

In a world in which dasatinib/quercetin, which costs ~$100 for a dose you take every year at most, does as well as the Unity candidates, will Unity be able to charge the high costs at a great enough volume required to keep the investors happy? Seems unlikely.

I think Oisin Biotechnologies turning up a year or two later in the clinic with a far superior gene therapy product, clearing near all senescent cells in near all tissues, and which can be adjusted rapidly and at low cost, is less of a threat. The market, every human being much over the age of 40, is truly enormous, and several large companies could operate without bumping into one another all that much.